An article worth reading courtesy of investorvillage. Copy the subject line into google and do a search for a link to the full article since the entire story can't be pasted here. Next week we could continue higher. GLTA
By Kristine Crane
Published: Saturday, March 9, 2013 at 8:38 p.m.
Last Modified: Saturday, March 9, 2013 at 8:38 p.m.
The symptoms could have been many things: a lump in her throat, a wheezing sound, fatigue that no longer allowed her “to run circles around everyone,” said a patient this week at Shands at the University of Florida who requested anonymity.
And the first diagnoses seemed relatively familiar: laryngitis, walking pneumonia — even a flare-up of the emphysema she'd had as a smoker.
But then one night an intense chest pain that roused her from sleep was so crippling that she had to investigate further.
The answer she looked for is not the one she wanted to hear: advanced stage small cell lung cancer.
“Not a good outcome,” she said. “They told me if I did nothing, I would only live a couple more weeks.”
Small cell lung cancer is the kind most commonly connected to smoking.
“I don't recall ever seeing a patient who was not a smoker,” said Dr. Frederic Kaye, the co-director of the thoracic oncology program at UF.
“Advanced stage small cell lung cancer is a very aggressive tumor,” Kaye added, and until recently, the same treatments had been used for about three decades — without much success.
But a new class of drugs that many believe is starting to change the course of cancer treatments may be making some headway with small cell lung cancer — and UF is among two dozen centers worldwide that are taking part in trials to test these drugs.
The drugs are known as antibody-drug conjugates. Commonly known as armed antibodies, and often described as missiles, they carry chemotherapy drugs that are unleashed only once the antibody reaches the targeted cell surface.